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The motivation for this study was to reduce physics workload relating to patient-
specific quality assurance (QA). VMAT plan delivery accuracy was determined from 
analysis of pre- and on-treatment trajectory log files and phantom-based ionization 
chamber array measurements. The correlation in this combination of measurements 
for patient-specific QA was investigated. The relationship between delivery errors 
and plan complexity was investigated as a potential method to further reduce 
patient-specific QA workload. Thirty VMAT plans from three treatment sites — 
prostate only, prostate and pelvic node (PPN), and head and neck (H&N) — were 
retrospectively analyzed in this work. The 2D fluence delivery reconstructed from 
pretreatment and on-treatment trajectory log files was compared with the planned 
fluence using gamma analysis. Pretreatment dose delivery verification was also car-
ried out using gamma analysis of ionization chamber array measurements compared 
with calculated doses. Pearson correlations were used to explore any relationship 
between trajectory log file (pretreatment and on-treatment) and ionization chamber 
array gamma results (pretreatment). Plan complexity was assessed using the MU/
arc and the modulation complexity score (MCS), with Pearson correlations used 
to examine any relationships between complexity metrics and plan delivery accu-
racy. Trajectory log files were also used to further explore the accuracy of MLC 
and gantry positions. Pretreatment 1%/1 mm gamma passing rates for trajectory 
log file analysis were 99.1% (98.7%–99.2%), 99.3% (99.1%–99.5%), and 98.4% 
(97.3%–98.8%) (median (IQR)) for prostate, PPN, and H&N, respectively, and were 
significantly correlated to on-treatment trajectory log file gamma results (R = 0.989, 
p < 0.001). Pretreatment ionization chamber array (2%/2 mm) gamma results were 
also significantly correlated with on-treatment trajectory log file gamma results 
(R = 0.623, p < 0.001). Furthermore, all gamma results displayed a significant 
correlation with MCS (R > 0.57, p < 0.001), but not with MU/arc. Average MLC 
position and gantry angle errors were 0.001 ± 0.002 mm and 0.025° ± 0.008° over 
all treatment sites and were not found to affect delivery accuracy. However, vari-
ability in MLC speed was found to be directly related to MLC position accuracy. 
The accuracy of VMAT plan delivery assessed using pretreatment trajectory log 
file fluence delivery and ionization chamber array measurements were strongly 
correlated with on-treatment trajectory log file fluence delivery. The strong corre-
lation between trajectory log file and phantom-based gamma results demonstrates 
potential to reduce our current patient-specific QA. Additionally, insight into MLC 
and gantry position accuracy through trajectory log file analysis and the strong cor-
relation between gamma analysis results and the MCS could also provide further 
methodologies to both optimize the VMAT planning and QA process. 
PACS number: 87.53.Bn, 87.55.Kh, 87.55.Qr
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I. INTRODUCTION
Volumetric-modulated arc therapy (VMAT) offers equivalent or higher conformity to target 
volumes and faster delivery times compared to step and shoot or dynamic intensity-modulated 
radiotherapy (IMRT).(1-2) VMAT is a system for intensity-modulated radiotherapy treatment 
delivery that achieves high dose conformality by optimizing the dose rate, gantry speed, and 
the leaf positions of the dynamic multileaf collimator. Thus, the delivery of VMAT is inher-
ently more complex than fixed gantry IMRT deliveries. This additional complexity has led 
to recommendations for additional machine-specific commissioning tests.(3-4) However, 2D 
patient-specific quality assurance (QA) methods used for IMRT delivery verification have 
been found adequate for verifying VMAT delivery accuracy.(5-7) Despite this, 3D verification 
procedures have been adopted into routine use to readily assess the effect of the rotating gantry 
on plan delivery.(8-10)
Currently, QA of both IMRT and VMAT treatment plans is time-consuming, putting sig-
nificant strain on resources in terms of machine time, plan preparation, and analysis.(11) There 
is a need to reduce physics workload, yet assure the quality of treatment deliveries is main-
tained. Although it is well documented that a single quality assurance check cannot detect all 
errors,(12,13) widespread debate has not led to a consensus on which combination of quality 
assurance checks would provide the most robust, efficient, economic resilience against treat-
ment delivery errors.(14-16) Furthermore, it has been suggested that errors detected pretreatment 
may not be representative of errors on-treatment(13,17) or, indeed, be clinically relevant.(18-20) 
The use of linear accelerator (linac) log files to verify VMAT delivery accuracy has been 
reported by several groups,(13,21-25) although confidence intervals by which to assess VMAT 
delivery accuracy (MLC speed and position, gantry speed and position and dose) for various 
treatment sites, are lacking in published data. Linac log file analysis has been proposed to 
improve efficiency of patient specific QA(13,22,23,26) and provide insight into machine parameters 
not possible with phantom-based measurements.(6,21,23,27) Additionally, linac log file analysis 
could be used to assess actual/relative delivered dose reconstructed on the patient’s anatomy 
using the patient’s original CT image set(21,24,28) or the on-treatment CBCT image set.(25) It has 
been suggested that linac log files, together with an independent check of the treatment planning 
system (TPS) dose calculation, could be an efficient, effective alternative to phantom-based 
patient-specific QA measurements.(13,24) Alternatively, others argue a phantom-based dosimetric 
measurement should continue as the mainstay of QA checks.(16) 
Assessment of plan complexity has been suggested as an alternative approach to reduce QA 
workload.(29-30) A measure of plan complexity that is related to delivery accuracy could identify 
less complex plans with a higher probability of achieving accurate delivery results. A number 
of complexity metrics have been proposed for step-and-shoot IMRT(29,31-32) and, of these, the 
modulation complexity score (MCS), which assesses the variability of leaf positions and aperture 
areas between segments, was found to be most sensitive to delivery and plan parameters.(33) 
The MCS has since been successfully adapted for assessment of planning parameters on VMAT 
plan complexity;(30) however, the relationship between VMAT plan complexity and deliver-
ability has not yet been explored in the literature.
This study investigated potential methods for reducing patient-specific QA. Delivery accu-
racy of thirty VMAT plans, delivered using Varian TrueBeam linacs, was determined from 
analysis of pre- and on-treatment trajectory log files and phantom-based ionization chamber 
array measurements. Delivery accuracy was assessed in terms of gantry angle and leaf position 
accuracy and through gamma analysis of 2D fluence and 3D dose distributions. The correlation 
in this combination of measurements for patient-specific QA was investigated. Additionally, the 
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relationship between gamma analysis results and plan complexity was explored as a potential 
method to further reduce patient-specific QA workload.
 
II. MATERIALS AND METHODS
Thirty VMAT patient plans encompassing three treatment sites — prostate only, prostate and 
pelvic node (PPN), and head and neck (H&N) — were retrospectively assessed in this work. The 
plans selected for each treatment site were from 10 consecutive patients treated in our center. 
All plans had been accepted for clinical treatment. Plans were generated in Eclipse (v.10.0.28), 
optimized using progressive resolution optimization algorithm (PRO v.10.0.28) and the final dose 
calculated using AAA v.10.0.28, with a 0.25 cm calculation grid size (Varian Medical System, 
Plato Alto, CA). Plans were created using 6 MV photon beams, and partial or full, single or dual 
arcs to optimize target coverage, with 177 control points per full arc, as set by the Eclipse TPS. 
All plans were delivered using two matched Varian TrueBeam V1.5 linear accelerators and 120 
leaf millennium MLCs (Varian Medical Systems). Plan statistics are summarized in Table 1. 
The MCS, which assesses plan complexity based on the variability of leaf positions, aperture 
area between segments, and segment weight as defined by McNiven et al.,(29) was determined 
with each control point considered as a beam segment. From this definition,(29) the MCS for a 
simple unmodulated field approaches 1, while the MCS for complex, highly modulated fields 
tends to 0. Following the VMAT patient-specific QA protocol used in our center, the delivery 
of all VMAT plans was assessed pretreatment using the OCTAVIUS 4D phantom with the 729 
ionization chamber array and assessment of trajectory log files (pretreatment QA). In addition, 
for this study, the trajectory log files recorded for every fraction for all plans over the entire 
course of treatment were analyzed (on-treatment QA).
A.  Pretreatment verification: OCTAVIUS 4D
Pretreatment dose delivery accuracy was determined using the OCTAVIUS 4D phantom (PTW, 
Freiburg, Germany), comprising the OCTAVIUS 729 2D ionization chamber array, located in 
a motorized cylindrical phantom with an angular range of ± 360°. The array rotates with the 
gantry, using an inclinometer attached to the gantry to determine the gantry angle, so that the 
detector array remains perpendicular to the incident beam, preventing errors due to the direc-
tional dependence of the detectors. The 2D array dose measurements were used at each gantry 
angle to create a 3D dose distribution. A single 3D dose delivery was then assessed for each 
plan with gamma analysis using VeriSoft v.5.1 analysis software (PTW, Freiburg, Germany), 
with a global 3%/3 mm and 2%/2 mm gamma criterion, normalized to a low-gradient region 
with a 10% minimum dose threshold. The minimum gamma criterion of 2%/2 mm was selected 
due to inherent uncertainties in setting up a geometric phantom.
Table 1. Summary of plan statistics.
 Prostate PPN H&N
Number of Patients 10 10 10
Fractionation 74 Gy in 37# 74 Gy in 37# 70 Gy in 35#
Average Field Size (cm2) 125.7±27.8 274.1±19.1 293.5±93.4
Average Number of Arcs (mean  ± 1 SD) 1.1±0.3 2±0 1.75±0.5
MCS(29) 0.395±0.064 0.302±0.055 0.237±0.067
MU/arc 478±92 325±35 324±101
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B.  Pretreatment verification: trajectory log file analysis
Trajectory log files recorded during pretreatment QA (minimum three deliveries per patient) 
were analyzed using in-house software written in MATLAB V.7.7.0 (MathWorks, Natick, 
MA) as previously described, with each control point considered as a beam segment.(26) Varian 
TrueBeam linacs record a single trajectory log file for each treatment arc. A single trajectory 
log file details the information for both MLC banks contained in the paired Clinac Dynalog 
files with the addition of couch position, dose-rate, beam energy, and absolute monitor units 
delivered.(23) Leaf positions (defined at the isocenter) and gantry angles (Varian IEC 601-2-1 
scale) recorded at the first position of each control point within the trajectory log file were 
compared to the planned delivery parameters contained in the RT DICOM plan as described by 
Eq. (1) and Eq. (2), respectively. Root mean squared (RMS), average, and standard deviation 
of leaf position errors per arc were used to quantify MLC leaf position accuracy. From Eq. (2), 
for a clockwise (CW) arc, a positive gantry angle error means the gantry rotates faster than 
planned. Similarly for a counterclockwise (CCW) arc, a positive gantry angle error means the 
gantry rotates slower than planned. To remove the effect of arc direction on gantry errors, gantry 
errors in CCW arcs were multiplied by a factor of -1 so that all positive gantry errors reflect a 
gantry moving faster than planned. Gantry position errors are described using the average and 
standard deviation of gantry angle errors over each arc. 
 MLC Position Error (mm) = MLC Planned Position - MLC Actual Position (1)
 Gantry Angle Error (deg) = Actual Gantry Angle - Planned Gantry Angle (2)
To further explore the mechanical delivery inaccuracies, actual MLC leaf velocity (cm/s) 
and gantry speed (deg/s) at each control point were approximated from trajectory log file data 
as described by Eq. (3) and (4), respectively.
  (3)
 
  (4)
 
where the numerator describes the distance travelled between two consecutive control points, 
n is an active MLC leaf and i is the CP number. The denominator describes the time between 
two consecutive control points, 0.02 s is the time resolution of the trajectory log file data, and 
LogFileSamples is the number of trajectory log file samples per control point, typically 17 
samples between CPi and CPi+1, depending on the dose rate and gantry speed.
Two-dimensional fluence delivery maps were reconstructed for each arc from the trajectory 
log file data as the relative sum of all control points, using the actual leaf positions and actual 
delivered MUs recorded at the first control point position within the trajectory log file. The 2D 
planned fluence maps were reconstructed using the equivalent control point data contained within 
the RT DICOM plan. Global gamma criteria 3%/3 mm and 1%/1 mm with a 10% minimum 
dose threshold were used to assess fluence delivery accuracy. The stricter 1%/1 mm gamma 
criterion was required to differentiate difficulties in plan deliveries.
C.  On-treatment verification: trajectory log file analysis
All trajectory log files for every fraction over the course of each patient’s treatment, total-
ing 1769 trajectory log files, were assessed retrospectively in comparison to the planned RT 
208  Agnew et al.: VMAT patient-specific QA and complexity scores 208
Journal of Applied Clinical Medical Physics, Vol. 15, No. 6, 2014
DICOM treatment delivery. Delivery parameters used for pretreatment QA, namely leaf posi-
tion accuracy, gantry position accuracy, and fluence delivery accuracy, were further assessed 
for all arcs over all patient fractions. 
D.  Statistical analysis
All results are presented as mean ± 1 SD, with the exception of gamma passing rate, which are 
presented as median (interquartile range (IQR)). Relationships between variables were explored 
using Pearson correlations (R). Results were deemed correlated for R > 0.5. Due to the sample 
size n = 30 for phantom-based measurements and > 1000 for trajectory log file measurements, 
all correlations with R > 0.5 were significant at p < 0.005 level.
 
III. RESULTS 
A.  2D fluence and 3D dose delivery accuracy
Results for 3D OCTAVIUS dose delivery accuracy and 2D trajectory log file fluence delivery 
accuracy pre- and on-treatment are shown in Table 2 and presented graphically in Fig. 1. Little 
variation was noted in 3%/3 mm gamma analysis across treatment sites or measurement devices. 
Stricter 2%/2 mm gamma criteria for OCTAVIUS and 1%/1 mm for trajectory log file analysis 
revealed variation in delivery accuracy across treatment sites. Gamma passing rates for H&N 
plans were reduced on all measurement devices. H&N plans were the most complex of all 
treatment sites investigated in this study (MCS: 0.237 ± 0.067). Pearson correlations revealed 
a relationship between MCS and OCTAVIUS 2%/2 mm gamma passing rates (R = 0.654, p < 
0.001), 1%/1 mm trajectory log file gamma passing rates pretreatment (R = 0.595, p < 0.001), 
and on-treatment (R = 0.571, p < 0.001). No significant correlations were noted for any gamma 
passing rates and the MU/arc. Of note, a relationship between OCTAVIUS 2%/2 mm gamma 
passing rate and delivery collimator angle was measured as illustrated in Fig. 1(a). This is due 
to an increase in the number of detectors irradiated at angles close to 45° from the normal, as 
previously reported.(10)
On-treatment trajectory log 1%/1 mm gamma results showed a strong correlation to pretreat-
ment trajectory log 1%/1 mm gamma results (R = 0.989, p < 0.001), as illustrated in Fig. 2(a). 
The interquartile ranges of on-treatment trajectory log gamma results were comparable to those 
acquired pretreatment, illustrating the consistency and reproducibility of VMAT deliveries 
over the course of treatment. A significant correlation was also noted between on-treatment 
trajectory log fluence delivery and pretreatment OCTAVIUS dose delivery results (R = 0.623, 
p < 0.001), as presented in Fig. 2(b).
Table 2. Pretreatment gamma passing rates for the OCTAVIUS and pretreatment and on-treatment gamma passing 
rates for trajectory log file analysis. Results are presented as median (IQR).
 Prostate PPN H&N 
  Gamma Median Range Median Range Median Range
Pretreatment
 OCTAVIUS 3%3mm 99.90 (99.70–100) 99.75 (99.20–99.90) 98.40 (96.98–99.70)
  2%2mm 97.25 (96.80– 98. 00) 96.50 (94.25–97.28) 90.00 (87.43–92.68)
 Log Files 3%3mm 99.99 (99.97–100) 100 (99.99–100) 99.99 (99.98–100)
  1%1mm 99.09 (98.70–99.23) 99.33 (99.10–99.48) 98.37 (97.34–98.82)
On-treatment
 Log Files 3%3mm 99.99 (99.98–100) 100 (99.99–100) 99.99 (99.98–100)
  1%1mm 99.15 (98.74–99.29) 99.25 (99.13–99.44) 98.47 (97.46–98.72)
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Fig. 1. Box plots of gamma passing rates for pretreatment verification using (a) OCTAVIUS (2%/2 mm), (b) pretreatment 
trajectory log files (1%/1 mm), and (c) on-treatment verification using trajectory log files (1%/1 mm). Results are stratified 
per treatment site - prostate (Pros), prostate and pelvic node (PPN), and head and neck (H&N). Boxes represent median 
and interquartile range (IQR). Whiskers represent the spread of the data. Outliers are denoted by open circles. The effect 
of collimator angles <15° on OCTAVIUS gamma passing rates is noted for H&N cases in Fig. 1 (a).
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B.  MLC position accuracy 
RMS MLC leaf position errors, average leaf position errors, and the standard deviation of leaf 
position errors were assessed per arc, per patient, and the mean and SD of these results are 
presented in Table 3. 
Average leaf position errors were negligible, < 0.005 mm over all treatment sites. However, 
the standard deviation and the RMS leaf position errors determined per patient illustrated that 
larger transient errors of up to 0.16 mm were present during the treatment delivery. Of note, 
the standard deviation and RMS of leaf position errors determined per patient were strongly 
correlated (R = 0.993, p < 0.001), as expected, due to the bias of both parameters to the larg-
est errors present in the analysis. These transient leaf position errors occurred where the MLC 
leaves were accelerating/decelerating, as illustrated in Fig. 3(a) for a single leaf from a sample 
prostate plan. The relationship between MLC errors and MLC acceleration/deacceleration was 
also evident from the strong correlation between RMS MLC errors and the standard deviation 
of MLC speed (R = 0.993, p < 0.001) for all plans as presented in Fig. 3(b). These transient 
leaf position errors were not related to the fluctuations in dose rate, as illustrated in Fig. 3(c). 
Average, RMS, and standard deviation of leaf position errors were not related to gamma deliv-
ery results (|R| < 0.3) for any measurement device. This may be due to the magnitude of these 
Fig. 2. Correlation between 2D trajectory log files on-treatment fluence delivery accuracy and (a) 2D trajectory log files 
pretreatment fluence delivery accuracy and (b) 3D OCTAVIUS pretreatment dose delivery accuracy. Circles represent 
median values and error bars represent the interquartile range (IQR).
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Table 3. Summary of trajectory log file mechanical delivery errors as a function of treatment site for prostate (Pros), 
prostate and pelvic node (PPN), and head and neck (H&N). Data are presented as mean ± 1 SD.
 Pros PPN H&N
Average Leaf Errors (mm) -0.001±0.002 0.001±0.002 0.001±0.003
Std Dev. Leaf Errors (mm) 0.134±0.009 0.162±0.009 0.138±0.012
RMS Leaf Errors (mm) 0.128±0.008 0.157±0.009 0.135±0.013
Gantry Angle Errors (deg) 0.025±0.006 0.024±0.005 0.026±0.012
Std Dev. Gantry Angle Errors (deg) 0.051±0.003 0.049±0.001 0.059±0.016
Fig. 3. MLC leaf position errors (a) and leaf velocity for a single leaf over all control points in a sample prostate treatment 
arc delivery. Large transient MLC errors occur where the leaf is accelerating/decelerating. The relationship (b) between 
average RMS MLC error per arc, per patient, and the variability in MLC leaf speed per arc, per patient, is plotted for all 
30 patients. MLC leaf position errors (c) for a single leaf and the fluctuations in dose rate over control points in the sample 
prostate treatment arc delivery.
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errors, of the order of 0.1 mm, while gamma analysis investigates positional errors > 1 mm for 
trajectory log files and > 2 mm in OCTAVIUS array measurements.
C.  Gantry position accuracy
Average gantry angle errors and the standard deviation of gantry angle errors were also assessed 
per arc, per patient, and the mean and SD of these results are presented in Table 3. Average 
gantry angle errors demonstrated a systematic gantry angle error of 0.025° over all treatment 
sites. The positive average gantry angle error indicates the gantry systematically rotated faster 
than planned for both CW and CCW arcs. Similar to MLC errors, the standard deviation of 
gantry angle errors revealed larger transient gantry angle errors were present during treatment 
deliveries. For deliveries with constant gantry speed, the gantry appeared to cyclically correct 
for position errors, as illustrated in Fig. 4(a) for a sample PPN plan and in sections of Fig. 4(b) 
for a sample H&N plan. With varying gantry speed, the gantry modified its position ad hoc, 
as illustrated in sections of Fig. 4(b). However, unlike MLC errors, this variability in gantry 
speed was not significantly related to variability in gantry errors (R = 0.356). Additionally, the 
cyclic corrections of gantry position were not found to be related to variations in dose rate, as 
illustrated in Fig.4 (c) and (d) for either the sample PPN of H&N plans. Average and standard 
deviation of gantry angle errors were also not related to gamma delivery results (|R| < 0.33) 
for all measurement devices, potentially due to the magnitude of these errors, of the order of 
0.03°. The OCTAVIUS phantom has previously been found to determine the gantry angle to 
within 0.4° of the nominal gantry angle,(10) thus detecting errors of the magnitude of 0.03° may 
be beyond the capabilities of the OCTAVIUS phantom. Furthermore, the accuracy of Varian 
C-series DynaLog file recorded gantry angles has been found to be 0.11°, which is at the limit 
for data collected in this work for TrueBeam trajectory log files.(34)
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Fig. 4. (a) and (c) illustrate gantry angle error for all control points in a sample PPN treatment arc: (a) shows with a con-
stant gantry speed, gantry angle is corrected cyclically; (c) shows no notable relationship between gantry angle error and 
dose rate. (b) and (d) illustrate gantry angle error for all control points in a sample H&N treatment arc: (b) again shows 
where the gantry speed is constant (central region), gantry angle is corrected cyclically, while during the initial and final 
control points of the arc, the gantry speed varies and the gantry angle position is corrected ad-hoc; (d) again shows no 
notable relationship between gantry angle error and dose rate.  
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IV. DISCUSSION
The accuracy of VMAT deliveries on Varian TrueBeam linacs recorded by trajectory log files 
has been determined for three treatment sites — prostate, prostate and pelvic node, and head 
and neck. Although such results have previously not been published for a cohort of patients, 
the errors reported in this work are comparable to QA results for an example VMAT TrueBeam 
delivery reported elsewhere.(23) Alternatively, VMAT leaf position and gantry angle errors 
reported with Varian C-Series DynaLog files are an order of magnitude larger than those reported 
in this work with TrueBeams.(21,35-37) Furthermore, contrary to this work, previous reports 
with Varian C-Series DynaLog files found the gantry rotated slower than planned.(37) These 
differences may be a consequence of the retrospective and prospective communication utilized 
within the TrueBeam, rather than the retrospective communication used in the previous C-Series 
linacs. This is in agreement with previously reported studies that demonstrated improvements in 
delivery accuracy between C-Series linacs and TrueBeam linacs for step-and-shoot IMRT.(27,38)
The consistency of on-treatment trajectory log file QA results and the relationship of on-
treatment QA results with pretreatment QA results validate the use of pretreatment QA as a 
surrogate for on-treatment delivery accuracy, although no pretreatment QA can mitigate against 
corruption of file data throughout the course of treatment. The direct correlation between 
trajectory log file analysis and OCTAVIUS results reveals a potential opportunity to reduce 
pretreatment patient specific QA. The use of linac log file pretreatment QA can ensure accu-
rate file transfer, machine delivery capabilities and fluence delivery accuracy before treatment 
delivery, and precludes the need to modify any treatment parameters following pretreatment 
verification. Furthermore, log file QA can be performed after the first fraction to ensure no 
treatment parameters were modified between pretreatment QA and the first treatment delivery, 
which requires no physics time on the treatment machine.(13,17) However, OCTAVIUS provides 
a completely independent dosimetric assessment of the delivery, whereas trajectory log files 
recorded by the treatment machine is not completely independent and assesses the fluence 
rather than the dose delivery. Additionally, linac log files may not detect MLC leaf calibration 
errors.(39) Therefore, removal of a phantom-based measurement from pretreatment QA may be 
justified, but only if combined with a routine independent check of the TPS dose calculation,(40) 
robust linac-specific QA, and routine and independent calibration of leaf encoder positions to 
ensure the accuracy of linac log file data.(39) In comparison to phantom-based measurements, 
linac log file analysis offers significant time-savings and greater sensitivity, and is capable 
of detecting delivery errors < 0.1 mm and < 0.1°, which is not possible with phantom-based 
measurements. Additionally, comparison of the linac log file with the original treatment RT 
DICOM maintains a direct connection with the patient treatment plan, a connection that could 
be broken by creation and recalculation of a phantom-based QA plan.(13)  
A further advantage of QA with linac log files is the potential to understand machine perfor-
mance. In this study, MLC position accuracy was found to be directly related to the fluctuations 
in MLC speed. A relationship between gantry position errors and gantry speed was also noted, 
although this was not significant and gantry angle errors measured were at the known limit of 
Varian C-series DynaLog file accuracy.(34) Neither MLC or gantry position accuracy were related 
to gamma passing rates, again possibly due to the magnitude of these small errors, thus indicating 
these delivery errors did not combine to clinically affect the delivery accuracy. Understanding 
machine performance could be used to guide the planning process, with improvements in the 
accuracy of MLC position possible with reduction in leaf speed variability.  
Previous studies have demonstrated that the MCS could be used to assess IMRT plan com-
plexity to assist the treatment planning and optimization process,(33) and improve the efficiency 
of the QA process by identifying less complex plans with a high probability of accurate dosim-
teric delivery.(29) Initial work applying the MCS metric to VMAT plans found that variations 
in treatment planning parameters affect VMAT plan complexity.(30) In this study, the MCS was 
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also found to be related to VMAT plan deliverability measured from gamma analysis of both 
2D fluence and 3D dose delivery maps. Thus the MCS, despite being developed for S&S IMRT 
and not considering the additional complexity in VMAT plans due to variability in MLC speed, 
gantry speed, and dose rate, could be used to assess the complexity of VMAT plans and, as with 
IMRT plans, could be a useful tool in both the planning and QA process. Furthermore, as the 
variability in MLC speed, but not gantry speed or dose rate, has been found to affect delivery, 
future work to incorporate MLC speed variability into a VMAT MCS will be undertaken to 
further refine this metric.
 
V. CONCLUSIONS
VMAT plan delivery, recorded by trajectory log files, for three treatment sites — prostate, 
prostate and pelvic node, and head and neck — was highly correlated with ionization chamber 
array measurements, illustrating the potential to reduce the patient-specific QA process currently 
utilized in our center. Trajectory log file analysis over the course of treatment was consistent, 
reproducible, and highly correlated with pretreatment QA measurements. Trajectory log file 
analysis revealed variability in MLC speed affected MLC position accuracy. Furthermore, tra-
jectory log file and ionization chamber array gamma results were dependent on plan complexity 
as assessed by the MCS. Thus, a reduction in the variability of MLC speed and the use of the 
MCS could be utilized to further optimize the VMAT planning process and the patient-specific 
QA workload. 
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